Stockreport

Viridian Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]

Viridian Therapeutics, Inc.  (VRDN) 
PDF All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue exceeded analyst estimates by 73%. Earnings per share (EPS) missed analyst est [Read more]